[18F]Fluorodeoxyglucose PET for Interventional Oncology in Liver Malignancy

Area of Science:

• Nuclear Medicine
• Oncology
• Radiology

Background:

• [(18)F]Fluorodeoxyglucose (FDG) PET provides metabolic information, potentially detecting lesions before anatomical changes.
• FDG-PET/computed tomography (CT) is valuable in oncology patient management.
• Previous accuracy studies often used small, retrospective cohorts.

Purpose of the Study:

• To provide an overview of FDG-PET or FDG-PET/CT's role in liver malignancies.
• To analyze its utility in patients undergoing specific liver-directed oncologic interventions.

Main Methods:

• Review of existing literature on FDG-PET and FDG-PET/CT in liver malignancies.
• Focus on studies involving surgical resection, ablative therapy, chemoembolization, radioembolization, and brachytherapy.

Main Results:

• FDG-PET/CT's ability to detect lesions metabolically before anatomical visualization is a key advantage.
• The article synthesizes evidence regarding its application across diverse liver-directed treatments.

Conclusions:

• FDG-PET/CT plays a significant role in the management of liver malignancies.
• Its functional imaging capability aids in treatment planning and monitoring for various liver-directed oncologic interventions.